title: Cerebrospinal fluid acetylcholinesterase activity after long-term treatment with donepezil and rivastigmina.
abstract: At present acetylcholinesterase (AChE) inhibitors (AChEIs) represent the only reliable therapeutic resource for symptomatic treatment of Alzheimer Disease (AD). This study was designed to assess the effects of 6-12 month treatment with AChEIs donepezil and rivastigmine on cerebrospinal fluid (CSF) AChE and butyrylcholinesterase (BuChE) activity in AD patients. The pattern of AChE isoforms (G4, G1, G2) before and after treatment was investigated as well. In AD patients treated with donepezil a significant increase of CFS AChE activity was observed, whereas treatment with rivastigmine induced a significant decrease of AChE activity. Both drugs did not change BuChE activity and tended to restore the physiological pattern of AChE isoform. The possible significance of the influence of AChEIs on CSF AChE activity and isoforms is discussed.
authors.affiliation: Department of Neuroscience, University of Perugia, Via E Dal Pozzo, 06126, Perugia, Italy.
authors.forename: S
authors.initials: S
authors.lastname: Amici
authors.forename: A
authors.initials: A
authors.lastname: Lanari
authors.forename: R
authors.initials: R
authors.lastname: Romani
authors.forename: C
authors.initials: C
authors.lastname: Antognelli
authors.forename: V
authors.initials: V
authors.lastname: Gallai
authors.forename: L
authors.initials: L
authors.lastname: Parnetti
mesh_terms: D000110:Acetylcholinesterase / Q000134:cerebrospinal fluid* / Q000378:metabolism; D000368:Aged; D000544:Alzheimer Disease / Q000134:cerebrospinal fluid / Q000188:drug therapy / Q000201:enzymology*; D002091:Butyrylcholinesterase / Q000134:cerebrospinal fluid / Q000378:metabolism; D002219:Carbamates / Q000627:therapeutic use*; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use*; D000077265:Donepezil; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007189:Indans / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D048448:Phenylcarbamates; D010880:Piperidines / Q000627:therapeutic use*; D020033:Protein Isoforms / Q000134:cerebrospinal fluid / Q000378:metabolism; D000068836:Rivastigmine; D013997:Time Factors
chemical_list: D002219:Carbamates; D002800:Cholinesterase Inhibitors; D007189:Indans; D048448:Phenylcarbamates; D010880:Piperidines; D020033:Protein Isoforms; D000077265:Donepezil; D000110:Acetylcholinesterase; D002091:Butyrylcholinesterase; D000068836:Rivastigmine